Navigation
banner

Ocular Diseases Drug Discovery

2017-11-182017-12-202017-11-20
EARLY BIRD DISCOUNT! Register by Nov 20, 2017 to receive 30% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


KEYNOTE SPEAKERS
Jerry Cagle

Jerry Cagle
Independent Pharmaceuticals Professional
Jerry Cagle
Independent Pharmaceuticals Professional
 
About Speaker:
Carl Romano

Carl Romano
Executive Director, Ophthalmology
Regeneron
Carl Romano
Executive Director, Ophthalmology
Regeneron
 
About Speaker:
DISTINGUISHED SPEAKERS
Matthias Birkhoff

Matthias Birkhoff
Vice President Marketing
Aptar Pharma
Matthias Birkhoff
Vice President Marketing
Aptar Pharma
 
About Speaker:

Matthias Birkhoff is Vice President, Marketing, of Aptar Pharma. In this role Matthias is responsible for Aptar Pharma’s Eye Care program and coordinates research and development activities, microbiological assessment and commercial strategies. Matthias started his career in pharmaceutical sales in a major multinational pharmaco before joining Aptar sixteen years ago.

Before getting involved in Business Development and Marketing, Matthias was in charge of sales in the AsiaPacific region. Matthias studied medicine at the University of Dusseldorf, Germany and holds a nursing degree.

Matthias has recently spoken at international events, such as NDD (Nasal Drug Delivery), London/UK, PMP (Pharmaceutical Plastics), Copenhagen/Denmark, Interphex, Tokyo/Japan, CPHI, Pharmapack, AAPS, or the IPA conference in Mumbai/India.

Larry Brown

Larry Brown
Chief Scientific Officer
Noveome Biotherapeutics, Inc.
Larry Brown
Chief Scientific Officer
Noveome Biotherapeutics, Inc.
 
About Speaker:
Jonca Bull

Jonca Bull
VP, Regulatory Consulting; Ophthalmology Therapeutic Area Director
PPD
Jonca Bull
VP, Regulatory Consulting; Ophthalmology Therapeutic Area Director
PPD
 
About Speaker:
Emmett Cunningham

Emmett Cunningham
Partner
Clarus Ventures
Emmett Cunningham
Partner
Clarus Ventures
 
About Speaker:
Mala Dutta

Mala Dutta
Lead, Office of Translational Research
NEI, NIH
Mala Dutta
Lead, Office of Translational Research
NEI, NIH
 
About Speaker: Mala Dutta completed her graduate studies in Immunology and T-cell signaling from the National Human Genome Research Institute (NHGRI), NIH, under the NIH-GWU Partnership Program. After brief post-doctoral research, she joined the Technology Transfer and Intellectual Property Office (TTIPO) at the National Institute of Allergy and Infectious Diseases (NIAID) as a Technology Development Specialist. She came on board the National Eye Institute’s Office of Translational Research as a Presidential Management Fellow and now leads the office in its technology development, collaboration, translational and inter-agency initiatives.
Rafal Farjo

Rafal Farjo
Founder and Chief Executive Officer
EyeCRO LLC
Rafal Farjo
Founder and Chief Executive Officer
EyeCRO LLC
 
About Speaker:
Mohamed Genead

Mohamed Genead
Chief Medical Officer
GenSight Biologics
Mohamed Genead
Chief Medical Officer
GenSight Biologics
 
About Speaker:

Mohamed Genead, MD Chief Medical Officer, GenSight Biologics Dr. Genead is an ophthalmologist and a fellowship-trained vitreoretinal surgeon and medical retinal specialist with more than 15 years of experience in Ophthalmology and Visual Sciences clinical research most recently served as Biogen Global Therapeutic Area Head of Ophthalmology and Retina Gene Therapy Areas, a senior leadership position of strategic importance and high visibility and part of Senior Management Team. Lead the global clinical development for execution of project strategies of early and late-stage development programs intended for regulatory approvals of Ophthalmology gene therapy and biological products.

Prior to joining Biogen, Dr. Genead was Global Head of Clinical Development at Allegro Ophthalmic, where he led the global clinical development teams for the LUMINATE (anti-integrin) platform in patients with vitreoretinal diseases (Wet AMD, DME, Posterior Vitreous Detachment). Set all US and International Clinical research strategies in support of Ophthalmology therapeutic area.

Prior to joining Allegro, Dr. Genead was Executive Medical Director and Global Project Team and Clinical Team Lead of early proof of concept and late registration clinical development programs in the ophthalmology/retina therapeutics area at Allergan, where he was leading tier-1 projects as DARPins for neovascular age-related macular degeneration and diabetic macular edema, and Brimonidine DDS implants for geographic atrophy. In addition, he served as subject matter and translational medicine expert on retina therapeutics and discovery. In addition, Mohamed was a key member of Ophthalmology due-diligence and external licensing teams. He was part of commercial and launching team for retina therapeutics with very in-depth knowledge about competitive landscape in Ophthalmology.

Before joining Allergan, Dr. Genead spent years in academic medicine serving as co-director of center of retina degenerative diseases, principle investigator as well as clinical scientist, Department of Ophthalmology and Visual Sciences, at the University of Illinois in Chicago. His area of academic interest focused on retinal novel therapeutics from ocular gene therapy to retina regenerative stem-cell therapies for orphan retina diseases such as Stargardt disease, retinitis pigmentosa. He was among the first in the world to get involved first human retina gene therapy trial. His team was a pioneer in using a topical eye drops to treatment macular edema associated with retinal dystrophy. Also, he discovered a new gene mutation inflicted in patients with Leber congenital amauroisis in collaboration with researchers at McGill University.

Dr. Genead has been a consultant to many ophthalmic biotechnology companies and healthcare venture firms. He is a member of numerous professional and honorary societies (i.e.; American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Society of Cell & Gene Therapy, International Society for Clinical Electrophysiology of Vision, American Society of Human Genetics). He also serves as a board member of several organizations and scientific advisory boards. He was the primary and key author for numerous peer-reviewed manuscripts in highly impact factor scientific journals (more than 70 manuscripts and 25 presentations) focusing on retina clinical research and novel therapeutics.

Dr. Genead graduated magna cum laude from the University of Chicago, and received his medical degree with honors and completed his residency in ophthalmology at Medical College of Wisconsin in Milwaukee. After completing his vitreoretinal fellowship at the University of Illinois in Chicago, he attended the Leadership Certificate Program at Southern Methodist University’s Cox School of Business, and went on to receive his executive management certificate from the University of Michigan Stephen Ross School of Business.

Judy Gordon

Judy Gordon
Founder & President
ClinReg Consulting Services, Inc
Judy Gordon
Founder & President
ClinReg Consulting Services, Inc
 
About Speaker:

Dr. Gordon is president of ClinReg Consulting Services, a clinical and regulatory consulting practice, and has taken multiple NDAs and PMAs through the FDA review process. She has been involved in conducting clinical trials and obtaining FDA approval for a broad range of drugs, biologics and devices including the first intravitreal sustained release drug delivery system (Vitrasert), intravitreal drugs/biologics for AMD and DME, drug delivery systems for glaucoma drugs, prostate cancer and other oncology drugs, combination products, injectable polymers for tissue bulking in GERD and urinary incontinence, drug-eluting sinus stents, CAD systems for tumor detection, coils and polymers for aneurysm treatment, intracranial stents for stroke prevention, breast biopsy devices, femtosecond lasers for LASIK and cataract surgery, phakic and accommodating phakic IOLs, excimer lasers, and other novel products.

Dr. Gordon has been active in chairing several industry-FDA working groups on guidance documents and has served as the industry representative to FDA’s Ophthalmic Devices Advisory Panel and the CDRH Dispute Mediation Panel

Pablo Gurman

Pablo Gurman
Chief Medical Officer
GearJump Technologies
Pablo Gurman
Chief Medical Officer
GearJump Technologies
 
About Speaker:
Brian Levy

Brian Levy
Chief Executive Officer
Ocunexus Therapeutics
Brian Levy
Chief Executive Officer
Ocunexus Therapeutics
 
About Speaker:

Brian Levy O.D., M.Sc., Chief Executive Officer, Ocunexus Therapeutics. Formerly Chief Medical Officer at Aerie Pharmaceuticals and prior to that Corporate Vice President R&D and Chief Medical Officer at Bausch & Lomb where he was responsible for 3 NDA’s for pharmaceuticals (Retisert, Zylet, Besivance) all FDA approved and currently in the market. On the device side of the business he was responsible for 4 PMA’s and multiple 510K’s. Prior to Bausch & Lomb he was Associate Professor, Department of Ophthalmology at California Pacific Medical Center in San Francisco and prior to that in private practice in Toronto and a clinical investigator and consultant to the ophthalmic industry. He received a Doctor of Optometry degree from the University of California at Berkeley and a Master of Science in comparative anatomy and physiology of the eye at U of Waterloo in Canada.

Charlie McDermott

Charlie McDermott
President & Chief Business Officer
Impact Biomedicines, Inc.
Charlie McDermott
President & Chief Business Officer
Impact Biomedicines, Inc.
 
About Speaker:
Neil Poloso

Neil Poloso
Director, Biological Research
Allergan
Neil Poloso
Director, Biological Research
Allergan
 
About Speaker:

Neil Poloso received his B.S. in Biology from the University of Delaware (1997) and Ph.D. in Immunology from Emory University (2002).  While at Emory University, he helped develop a method of deriving cancer vaccines from primary tumor tissue using protein transfer of lipid-linked immune-stimulatory molecules.  Following graduate school, Dr. Poloso moved to the National Cancer Institute for a postdoc in the laboratory of Paul Roche studying protein trafficking in antigen presenting cells.  While there, he published three papers on the association of MHC class II with lipid rafts.  Following his time at the NCI, Dr. Poloso moved into the biotech industry, first with Alba Therapeutics, working on characterizing immune effects of their lead compounds for Celiac disease, and shortly thereafter moving to Allergan, Inc. (2008) in Irvine, CA.  At Allergan, Dr. Poloso is currently a Director of Biological Research working to discovery of new therapeutics in the areas of prostaglandins and prostamides in inflammation, hair biology, and metabolic disease.

Christian Roesky

Christian Roesky
CEO & Managing Director
Novaliq
Christian Roesky
CEO & Managing Director
Novaliq
 
About Speaker:
Derek Welsbie

Derek Welsbie
Assistant Professor, Ophthalmology
University of California, San Diego
Derek Welsbie
Assistant Professor, Ophthalmology
University of California, San Diego
 
About Speaker:
Daniel White

Daniel White
CEO
Clearside Biomedical
Daniel White
CEO
Clearside Biomedical
 
About Speaker: Mr. White is a founder of Clearside Biomedical and has served as the President and Chief Executive Officer and as a member of our board of directors since our inception in May 2011. From 2008 to 2011, Mr. White served as Executive Director, Global Corporate Development, for Stiefel Laboratories, Inc., a dermatology pharmaceutical company acquired by GlaxoSmithKline in 2009. From 2007 to 2008, he co-founded and served as President and Chief Executive Officer of Percept BioScience, Inc., a biotechnology company. In 2003, Mr. White co-founded, and until 2007 served as Vice President of Finance and Corporate Development of Alimera Sciences, Inc., a biopharmaceutical company focused on ophthalmology. Previously he was Head of Business Development and Licensing for CIBA Vision, a Novartis company, and Director of Licensing and Business Development for AAIPharma. Mr. White holds an M.B.A. degree from Wake Forest University and a B.S. degree in molecular biology from Auburn University.